COMPANY
Eleison Pharmaceuticals
Timeline
- Trial start Phase 3: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer source ↗
- Trial start 2: Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma source ↗
- Trial start Phase 2: Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma source ↗
- Trial start Phase 2: Safety and Efficacy Study of Glufosfamide in Ovarian Cancer source ↗
Upcoming milestones
- 2028-03 (ESTIMATED) · Phase 3 · Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer · NCT01954992
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT01954992 | Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | Phase 3 | Recruiting | 2014-04 | 2028-03 (estimated) |
| NCT01650090 | Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma | 2 | Completed | 2012-08 | 2018-11 (actual) |
| NCT00441467 | Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma | Phase 2 | Completed | 2007-03 | 2008-10 (actual) |
| NCT00442598 | Safety and Efficacy Study of Glufosfamide in Ovarian Cancer | Phase 2 | Terminated | 2007-01 | 2008-04 (actual) |